



250 years of EXCELLENCE in
medical education, research &
innovation and healthcare

SEMMEWEIS UNIVERSITY

Faculty of Medicine

Department of Pharmacology and Pharmacotherapy

Director

Péter Ferdinandy, MD, PhD, DSc, MBA

IN MEMORIAM JÓZSEF KNOLL (1925-2018) SYMPOSIUM The future of deprenyl in pharmacotherapy

*Semmelweis Salon, Semmelweis University (H-1085 Budapest, Üllői út 26. I. floor)
October 15, 2019*

16.00 Péter Ferdinandy (Budapest, Hungary) – Opening of the Symposium

1.) **Ildikó Miklya** (Budapest, Hungary) – Chronology of the milestones in deprenyl research:
in memoriam József Knoll

16.05-16.25

2.) **Shizuko Muraoka** (Osaka, Japan) – The Selegiline (Deprenyl) Story in Japan: History of Cooperation
between Dr. Joseph Knoll and Fujimoto Pharmaceutical Group

16.25-16.40

3.) **Fabio Di Lisa** (Padua, Italy) – Crucial relevance MAO-B in diseases of cardiac and skeletal muscles

16.40-17.00

4.) **Péter Ferdinandy** (Budapest, Hungary) - Obesity and MAO-B inhibition

17.00-17.20

17.20 – 17.40 Coffee Break

5.) **Dóra Zelena** (Budapest, Hungary) – Enhancer's (deprenyl and BPAP) effect on stress

17.40-18.00

6.) **Kornélia Baghy** (Budapest, Hungary) – Tumor-manifestation suppressing effect of deprenyl and
BPAP

18.00-18.20

7.) **László Hársing Jr.** (Budapest, Hungary) - Neurotransmission activity enhancer mechanisms (effects
on dopaminergic neurotransmission)

18.20-18.40

Péter Ferdinandy (Budapest, Hungary) – Closing remarks

If you wish to attend the symposium, please send your reply to: pharmacology@med.semmelweis-univ.hu